This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Jesse Dong, Ph.D.
Vice President, Peptide Chemistry at BioNTech US


Jesse Z. Dong, Ph.D., is Vice President, Peptide Chemistry at BioNTech US. At BionTech US, he is leading the peptide chemistry activities of developing neoantigen-targeted therapies, process development, and technical support for GMP manufacturing of peptides. Previously, Jesse worked at Ipsen as Vice President of Compound Discovery, heading global Peptide Chemistry Division and leading peptide-based R&D programs. He is the inventor of TYMLOS™ (Abaloparatide), Setmelanotide, Relamorelin, TBR-760, and TBR-065. Some of these inventions led to the formations of Radius Health, Rhythm Pharmaceuticals, Motus Therapeutics, and Tiburio Therapeutics, respectively. Jesse is named inventor or co-inventor on 72 issued US patents and over 80 US patent applications. He is a co-author of 148 publications and abstracts.

Agenda Sessions

  • Panel Discussion Moderator and Panelists

  • Personal Neoantigen Vaccine NEO-PV-01

    On Demand